Nuformix (FRA:1RT) FCF Margin %: 0.00% (As of Mar. 2026)


What is Nuformix FCF Margin %?

Nuformix FRA:1RT FCF Margin % is 0.00% as of Mar. 2026. The stock has 1 warning sign investors should review. Among 959 Biotechnology companies, Nuformix ranks worse than 104275.18% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Nuformix's Free Cash Flow for the six months ended in Mar. 2026 was €-0.46 Mil. Nuformix's Revenue for the six months ended in Mar. 2026 was €0.00 Mil. Therefore, Nuformix's FCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Nuformix's current FCF Yield % is -13.46%.

The historical rank and industry rank for Nuformix's FCF Margin % or its related term are showing as below:


During the past 10 years, the highest FCF Margin % of Nuformix was -53.44%. The lowest was -10880.00%. And the median was -431.63%.

FRA:1RT's FCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -84.65
* Ranked among companies with meaningful FCF Margin % only.

Nuformix FCF Margin % Related Terms

Nuformix FCF Margin % Historical Data

* Premium members only.

The historical data trend for Nuformix's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nuformix FCF Margin % Chart

Nuformix Annual Data
Trend Dec15 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Sep24 Sep25
FCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -432.02 -2,683.33 0.00 0.00 0.00

Nuformix Semi-Annual Data
Dec15 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Mar24 Sep24 Mar25 Sep25 Mar26
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

FRA:1RT vs VRTX, REGN, ALNY: FCF Margin % Comparison

For the Biotechnology subindustry, Nuformix's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nuformix FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nuformix's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Nuformix's FCF Margin % falls into.


Nuformix FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Nuformix's FCF Margin for the fiscal year that ended in Sep. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Sep. 2025 )/Revenue (A: Sep. 2025 )
=-0.708/0
= %

Nuformix's FCF Margin for the quarter that ended in Mar. 2026 is calculated as

FCF Margin=Free Cash Flow (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-0.456/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of 0.00% mean?
Nuformix (FRA:1RT) has a FCF Margin % of 0.00% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Nuformix and its competitors. According to the industry distribution chart, Nuformix ranks #999999 out of 959 companies in the Biotechnology industry.
Is Nuformix's FCF Margin % too high?
Nuformix's current FCF Margin % is 0.00%. Based on the distribution chart, Nuformix ranks #999999 out of 959 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Nuformix's FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nuformix ranks #999999 out of 959 companies for FCF Margin %. This places Nuformix in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Nuformix and its competitors. Nuformix's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nuformix stock overvalued right now?
Nuformix (FRA:1RT) has a current FCF Margin % of 0.00%. The current FCF Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Nuformix (FRA:1RT), the current FCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nuformix Business Description

Other Exchanges NFX:UK1RT:Germany
Address C/O Arch Law Limited, 8 Bishopsgate, Huckletree Bishopsgate, London, GBR, EC2N 4BQ
Nuformix PLC is a pharmaceutical development company. It operates in pharmaceutical development, targeting unmet medical needs in fibrosis and oncology through drug repurposing. Its pipeline products include NXP001, NXP002, and NXP004. Geographically, the company operates only in the UK.